Literature DB >> 14515056

Does the CYP3A5*3 polymorphism affect in vivo drug elimination?

Kenneth E Thummel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14515056     DOI： 10.1097/00008571-200310000-00001

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  4 in total

Review 1.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

2.  Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

Authors:  Mari Thörn; Niklas Finnström; Stefan Lundgren; Anders Rane; Lars Lööf
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

3.  Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

Authors:  M A Perera; R K Thirumaran; N J Cox; S Hanauer; S Das; C Brimer-Cline; V Lamba; E G Schuetz; M J Ratain; A Di Rienzo
Journal:  Pharmacogenomics J       Date:  2008-09-30       Impact factor: 3.550

4.  CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin.

Authors:  Jin-Woo Park; Jong-Min Kim; Hwa-Young Lee; Jihyeon Noh; Kyoung-Ah Kim; Ji-Young Park
Journal:  Pharmaceutics       Date:  2022-07-18       Impact factor: 6.525
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.